Member Info for GIVMESUNSHINE

I dont think anyone on here knows what discussions are taking place, However why sweat it on every piece of assumed news ? This is not a one tricky pony - and vaultations of BIO have been hammered, plus weve most likely reached a peak in interest rates.. buy low sell high .. last 3 rns's are well worth the SP - CIRT/BUPA on its own

Hi Dug, Your call , but seems a bit of a knee Jerk reaction.. The company has made it clear for some time that it was not focusing on thre NHS /NICE at this point in time, they belive the money is in the US private sector.. for me PSE is not the revenue driver..CIRT is what will drive the perfonace of the company this year..

BTW Website traffic for 94percent was up 416% in October over September - number need to be taken with a large pinch of salt as the site didnt even register on google at first - Good Luck to you

I agree Dug - Not to be blinkered though, alway worth looking at the negatives, However rubbish about listing on the US aetc and useless Management are just rumblings from buying in too high .. Revenue wise Im not exptecting firework in the H2 numbers - OBD have already stated they block apply for reinbursment and do not reconise revunes until its paid, which mean the revs for H2 31sept .. will stop end of June / Maybe July. So we can pretty much works those out ourselves already. For me its the monthly run rate on CIRT Thats the Key, Its the product that has now had time to start to payback and last snapshot was very exciting . PSE can wait, It will take time to penetrate .. Loads of news to come , Happy to sit here an read the rubbish on here for now :)

To go from concept to launch and medicare code in a tad over 6 months,- is an unbelivable achievement, totally unheard of.. Never seen that in 30 years of investing.and after securing BUPA and 40%+ of the UK private insuremnt market for Cirt, Now I'm bored and managemet are usless, selling out at a loss.. bonkers .. If these board are a snapshot of the investing world we are all doomed to going back to the caves... Gambling is not investing

Agree - lots of ST buys chasing spikes ,leads to drip sells.. AIM is full of gamblers with the attention span of a goldfish.. Way too much going on to even risk not keep this as a core holding.. All good.. I dont think NHS is the priority for PSE myself - As per Cirt , penetrate the private sector first US with UK Private / BUPA in tandem..

Steves Bio, lets hope he can better his performance at OBD

I am a scientist by training who dove into business development in 2006 and hasn't looked back. Seventeen year track record in the CRO and Diagnostic space with increasing revenues and responsibilities. Grew the West Region with Caprion/Caprion-HistoGeneX/CellCarta 36x in 4 years. My skills are in Pharmaceutical client discovery, development, and management, presentations, contract development and negotiation, companion diagnostics co-development, and marketing.

Morning = Yes looks a good strong appointment.. Punching by getting him, looks a great addition.. OBD is really showing so determination and momentum at the moment .

Krull - More like loss takers buying on a spike, then selling out after a day or less.. still go the other 9% floating around somewhere in cyberspace... GLA

Cellcarta will make a great partner - over 1000 employess and leader in Biomarker Services

As a global Contract Research Organization Laboratory (CRO) to the biopharmaceutical industry, CellCarta provides access to a broad offering of biomarker platforms and services. We partner with you to address the most complex scientific testing needs, delivering customized biomarker testing solutions to further the limitless potential of precision medicine.

Worth looking into this guy and the company he worked for , impressive recruitment. I think it will take time and hard work to get PSE fully into the market, Reveune growth this year is going to come vastly from Cirt which is a company maker of many times the market cap on it own and approaching critcal mass..that is the key to growing the company and supporting additional products. Today news is another step pushing the company forwards

Its doing the rounds on a few brazilian websites

LSE removing part of the link -Just search

streia-campanha-sincera-sobre-cancer-de-prostata-quando-voce-vai-liberar-esse-c.

in google news , then translate

nice find - link doesnt work .. good to see the brazilian press on this

https://oglobo.globo.com/saude/noticia/2023/11/06/antonio-***undes-estreia-campanha-sincera-sobre-cancer-de-prostata-quando-voce-vai-liberar-esse-c.ghtml

I disagree , by time the announce profitabilty it will be much to late to buy in, anyone with a brain should be looking 12 month infront of that date - what the market need need is the confidence that the company will grow to become profitable at scale and not burn through investors money.- that is just a smidge too early at the moment , but BUPA , Medicare and the growth curve thus far are all nudging in the strongly right direction from proof of concept to seroius growth.. Market cap v potential 90% margin high volume is very low, even in this market - Many cash burners much further away from profit with less pointetial and many more mid tern obsticales to overcome at significant premiums to OBD.

Really don’t think the market has took in the significance of the BUPA deal for CiRT… It’s came on the back of 2 blockbuster an and all had a good news hangover IMO .. In one full swoop. CiRT is available to BUPA s 41% share of the UK heath insurance that’s over 2.3 million people + now covered for and offered a CiRT test should they sadly ever need it - BUPA are huge over 40million world wide .. It’s a big door to kick down.. and a real sign of where this is going .. if they can get BUPA they can get much more

Aklee

You only have to sell 400 CiRT for a $1 million in Revs at a 90% gross margin

I think perhaps Mr Odey called on of his mates at AL - offloaded OAMs OBD shares by buying them off OAM himself (at a discount) via a AL nominee account - privacy assured … it looked a very odd set up -

I hadn’t put the two together - didn’t realise this scandal was linked to us .. what an idiot .. now it’s obvious - only answers half the puzzle - who snapped up the rest ?

Details on the flaw in the current rules below..

The report also highlights how flaws in the register of owners of UK companies – known as the ‘PSC Register’ – could also be facilitating corruption. Currently, nominees and trustees owning shares are not required to tell Companies House who they are acting for. The government is opposing an amendment by Lord Vaux that would bring transparency to these arrangements.

I think its odd that this vehicle has been used .. possibly giving the overall purchaser anonymity